ArticleESMO open2026
Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Who cites it
7 citing papers in PubMed.
- First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.Nature medicine · 2026Trial
- Importance of Inclusion of Representative Populations in Pivotal Clinical Trials: Zolbetuximab as an Example.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma.Medical oncology (Northwood, London, England) · 2026Review
- Article
- Management of nausea and vomiting with claudin 18.2-targeted therapy in upper gastrointestinal cancer.ESMO gastrointestinal oncology · 2026Article
- Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer.ESMO gastrointestinal oncology · 2026Article
- Zolbetuximab-associated adverse event reporting signals in gastric cancer: a FAERS disproportionality analysis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the phase III SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) trials, nausea and/or vomiting were the most common adverse events in patients receiving zolbetuximab plus chemotherapy. We further characterize the adverse effects of nausea/vomiting on treatment adherence and efficacy, and evaluate strategies for managing nausea/vomiting through the SPOTLIGHT and GLOW combined analysis. MATERIALS AND
methodsAd hoc exploratory analyses included treatment discontinuations, antiemetic use, and progression-free survival (PFS) and overall survival (OS) after censoring patients with inadequate dose exposure (<75% relative exposure intensity) or early discontinuation (within 63 days) of zolbetuximab or placebo initiation.
resultsThis combined analysis included 1072 patients. Nausea and/or vomiting (nausea/vomiting) were most common on the first zolbetuximab infusion day [nausea: 46.5% (246/529); vomiting: 41.0% (217/529)]; on the second infusion day, nausea dropped to 23.2% (97/418) and vomiting dropped to 24.4% (102/418). Nausea/vomiting continued to decline on subsequent infusion days. More patients on zolbetuximab versus placebo had nausea/vomiting leading to inadequate dose exposure or early discontinuation [9.9% (53/537) versus 0.6% (3/535)]. More white than Asian patients had nausea/vomiting leading to inadequate dose exposure or early discontinuation with zolbetuximab [15.4% (36/234) versus 4.7% (12/254)] and placebo [0.9% (2/224) versus 0.4% (1/255)]. Before censoring, median PFS (mPFS) (hazard ratio) for zolbetuximab versus placebo was 9.2 versus 8.2 months (0.71), and median OS (mOS) was 16.4 versus 13.7 months (0.77). After censoring, mPFS was 10.4 versus 8.2 months (0.65), and mOS was 17.9 versus 13.7 months (0.69). On the first zolbetuximab infusion day, patients without vomiting had higher utilization of three-drug prophylactic regimens than those with vomiting [75.3% (73/97) versus 24.7% (24/97)]. In patients receiving steroids, including as antiemetic prophylaxis, mPFS was 10.5 months with zolbetuximab versus 8.3 months with placebo (0.66), and mOS was 18.4 versus 13.8 months (0.71).
conclusionOptimal antiemetic prophylaxis, with >3 drug classes including steroids, for zolbetuximab-associated nausea/vomiting is important for treatment adherence and maximal clinical benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.